Payment overview · 2025
General Payments
$132.67
6 reported records · 4 companies
Healthcare provider profile · identity verified
Dwane Gerard Broussard, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOUSTON, TX · NPI 1902801004
Verified facts
What the public records show
CMS Open Payments records show Dwane Gerard Broussard, M.D. received $132.67 in general payments during 2025 across 6 reported records.
PFIZER INC. accounted for 53.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $71.49 | 53.9% | 3 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $27.29 | 20.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.29 | 13.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.60 | 12.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $132.67 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $71.49 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $71.49 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $71.49 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 91 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1107 | 362 |
| Amlodipine Besylate | Amlodipine Besylate | 737 | 245 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 653 | 206 |
| Lisinopril | Lisinopril | 557 | 171 |
| Levothyroxine Sodium | Levothyroxine Sodium | 521 | 165 |
| Metformin Hcl | Metformin Hcl | 455 | 132 |
| Losartan Potassium | Losartan Potassium | 399 | 134 |
| Simvastatin | Simvastatin | 329 | 100 |
| Omeprazole | Omeprazole | 308 | 94 |
| Gabapentin | Gabapentin | 291 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 265 | 90 |
| Tramadol Hcl | Tramadol Hcl | 262 | 52 |
| Metformin Hcl Er | Metformin Hcl | 245 | 84 |
| Zolpidem Tartrate | Zolpidem Tartrate | 227 | 40 |
| Allopurinol | Allopurinol | 218 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 204 | 64 |
| Sertraline Hcl | Sertraline Hcl | 203 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 62 |
| Alendronate Sodium | Alendronate Sodium | 184 | 62 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 182 | 39 |
| Alprazolam | Alprazolam | 180 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 61 |
| Azithromycin | Azithromycin | 175 | 161 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 168 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 158 | 64 |
| Glimepiride | Glimepiride | 151 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 150 | 51 |
| Trazodone Hcl | Trazodone Hcl | 140 | 47 |
| Carvedilol | Carvedilol | 131 | 40 |
| Ezetimibe | Ezetimibe | 124 | 46 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 122 | 39 |
| Meloxicam | Meloxicam | 120 | 53 |
| Valsartan | Valsartan | 118 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 112 | 39 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 111 | 34 |
| Furosemide | Furosemide | 108 | 39 |
| Potassium Chloride | Potassium Chloride | 105 | 36 |
| Eliquis | Apixaban | 101 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 98 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 94 | 61 |
| Ozempic | Semaglutide | 91 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 88 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 24 |
| Montelukast Sodium | Montelukast Sodium | 79 | 26 |
| Irbesartan | Irbesartan | 75 | 22 |
| Jardiance | Empagliflozin | 70 | 18 |
| Clonazepam | Clonazepam | 64 | 13 |
| Finasteride | Finasteride | 63 | 23 |
| Fenofibrate | Fenofibrate | 62 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 54 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 13 |
| Lorazepam | Lorazepam | 59 | 17 |
| Valacyclovir | Valacyclovir Hcl | 59 | 29 |
| Mupirocin | Mupirocin | 58 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 15 |
| Synthroid | Levothyroxine Sodium | 57 | 21 |
| Famotidine | Famotidine | 56 | 22 |
| Ketoconazole | Ketoconazole | 52 | 31 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 52 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 15 |
| Celecoxib | Celecoxib | 43 | 22 |
| Sildenafil Citrate | Sildenafil Citrate | 43 | 15 |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Glipizide | Glipizide | 39 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 39 | 13 |
| Acyclovir | Acyclovir | 38 | 16 |
| Atenolol | Atenolol | 38 | 13 |
| Clonidine Hcl | Clonidine Hcl | 38 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | 15 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 37 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 35 | 15 |
| Memantine Hcl | Memantine Hcl | 35 | 16 |
| Glipizide Er | Glipizide | 33 | 12 |
| Pregabalin | Pregabalin | 33 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 25 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Spironolactone | Spironolactone | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Metronidazole | Metronidazole | 24 | 18 |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 20 |
| Baclofen | Baclofen | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Cefdinir | Cefdinir | 21 | 20 |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 18 |
| Cephalexin | Cephalexin | 20 | 20 |
| Methylprednisolone | Methylprednisolone | 20 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Prednisone | Prednisone | 16 | 12 |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Tadalafil | Tadalafil | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Colchicine | Colchicine | 14 | 12 |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | 12 |
| Telmisartan | Telmisartan | 13 | suppressed |
| Tobramycin | Tobramycin | 13 | 12 |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $132.67 · 6 records | PFIZER INC. | ABRYSVO, COMIRNATY, INSPIRE, Ozempic, PREVNAR 20, Rybelsus | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error